Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


China’s Stem Cell Industrialization Project In Jiangsu Starts Construction

This article was originally published in PharmAsia News

Executive Summary

The national bioindustry base's stem cell industrialization project recently commenced construction in Taizhou, China's medical city in Jiangsu province. Projects to be built include centers for stem cell technology transfer, testing and clinical application services as well as Phase II of the Jiangsu stem cell bank. The bank can house one million specimens and is set to be Asia's largest stem cell bank upon completion (PharmAsia News, March 23, 2008). The commercialized base will be a comprehensive facility integrating stem cell storage, application and technology transfer. ShenZhen BeiKe Bio-Tech is investing in the base through its wholly-owned subsidiary Jiangsu Beike. The firm has collaborations with 30 local healthcare institutions on clinical research including optic nerve hypoplasia, progressive myodystrophy, cerebral palsy, paraplegia and myocardial infarction. (Click here for more - Chinese language)

Related Content

BeiKe Bio-Tech To Set Up Asia’s Largest Stem Cell Base



Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts